Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  Careers at Hemispherx  


 

Hemispherx Biopharma Investor Relations

Welcome to Hemispherx Biopharma Investor Relations! In this section you can view the most recent Hemispherx press releases, SEC filings, including the 10K & 10Q, as well as obtain the contact information for the Company's Investor Relations contact, transfer agent and auditor. You may also request to receive news releases by e-mail.

Recent News:

 

10/30/2014 Hemispherx Biopharma Reports New Evidence – Based Potential of Ampligen® Against Ebola Virus Disease (EVD) … Ebola VP35-Induced Sequestration of a Critical Antiviral/Immune Activator is Responsible for High Mortality: A New Drug Target

10/20/2014 Hemispherx Announces Strategic Relationship with Squire Patton Boggs, Washington, DC as Governmental Counsel in Fight Against Ebola

10/20/2014 Hemispherx Biopharma Prevails in Multi-Million Dollar Federal Lawsuit
… All Claims by Cato Capital Dismissed by Federal Judge Company Seeks One Million Dollar Award for Fees and Costs Against Losing Party


10/7/2014 Hemispherx Biopharma Director Dr. William Mitchell to Present Research on Treating Deadly Emerging Viruses During the 4th World Congress on Virology October 8
Dr. Mitchell Will Chair Session with Prominent Scientist from the Centers for Disease Control and Prevention


9/29/2014 Hemispherx Biopharma Expands Research on Potential Ebola Treatments to Five Independent Experts/Institutional Collaborators … Hemispherx’s Two Experimental Therapeutics May Provide Benefit Despite Recently Discovered Ebola Viral Mutations

More Releases...

Click Here for a complete archive

Transfer Agent

Continental Stock Transfer & Trust Company
Shareowner Services
2 Broadway
New York, New York 10004 
Tel: 212-509-4000
Fax: 212-509-5150

Independent Public Accountants

McGladrey & Pullen, LLP

 

Investor Relations:

Charles Jones
CJones & Associates Public Relations
888-557-6480
cjones@cjonespr.com